Generic Slynd Availability
Last updated on Apr 10, 2025.
Slynd is a brand name of drospirenone, approved by the FDA in the following formulation(s):
SLYND (drospirenone - tablet;oral)
-
Manufacturer: EXELTIS USA INC
Approval date: May 23, 2019
Strength(s): 4MG [RLD]
Is there a generic version of Slynd available?
No. There is currently no therapeutically equivalent version of Slynd available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Slynd. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Patent 10,179,140
Issued: January 15, 2019
Inventor(s): Perrin Philippe & Drouin Dominique & Boyer-Joubert Cecile
Assignee(s): Laboratorios Leon Farma SAA pharmaceutical composition comprising an active contraceptive drug and one or more pharmaceutically-acceptable excipients. The pharmaceutical composition, when subjected to an in vitro dissolution test according to the USP XXIII Paddle Method, results in no more than 50% of said active drug initially present being dissolved within 30 minutes, and at least 50% of the active drug being dissolved in a time range from about 3 hours to about 4 hours. The pharmaceutical composition is administered daily to a patient having a BMI of about 25 kg/mor more for at least a portion of a treatment cycle. The pharmaceutical composition does not cause a number of days of bleeding events in the patient exceeding an average of 15% per treatment cycle in consecutive treatment cycles of administration after an initial treatment cycle of administration.
Patent expiration dates:
- June 28, 2031✓
- June 28, 2031
-
Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Patent 10,603,281
Issued: March 31, 2020
Inventor(s): Perrin Philippe & Velada Jose Luis & Drouin Dominique
Assignee(s): Laboratorios Leon Farma SAThe present invention relates to pharmaceutical compositions and kits comprising pharmaceutical compositions, and methods for administering pharmaceutical compositions comprising active contraceptive drugs in a patient. Specifically, the pharmaceutical compositions may comprise progestogen-only contraceptive (“POC”), such as Drosphirenone.
Patent expiration dates:
- June 28, 2031✓
- June 28, 2031
-
Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Patent 10,849,857
Issued: December 1, 2020
Inventor(s): Perrin Philippe & Velada Jose Luis & Drounin Dominique
Assignee(s): LABORATORIOS LEON FARMA SAThe present invention relates to pharmaceutical compositions and kits comprising pharmaceutical compositions, and methods for administering pharmaceutical compositions comprising active contraceptive drugs in a patient. Specifically, the pharmaceutical compositions may comprise progestogen-only contraceptives (“POC”), such as Drospirenone.
Patent expiration dates:
- June 28, 2031✓✓
- June 28, 2031
-
Synthetic progestogens and pharmaceutical compositions comprising the same
Patent 10,987,364
Issued: April 27, 2021
Inventor(s): Perrin; Philippe et al.
Assignee(s): LABORATORIOS LEON FARMA SA (Leon, ES)Described herein are synthetic progestogens, such as 6β,7β:15β,16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone, as well as pharmaceutical compositions comprising the same. Also described are methods of use.
Patent expiration dates:
- June 28, 2031✓
- June 28, 2031
-
Synthetic progestogens and pharmaceutical compositions comprising the same
Patent 11,123,299
Issued: September 21, 2021
Inventor(s): Perrin Philippe & Velada Jose Luis & Drouin Dominique
Assignee(s): LABORATORIOS LEON FARMA SADescribed herein are synthetic progestogens, such as 6β,7β:15β,16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone, as well as pharmaceutical compositions comprising the same. Also described are methods of use.
Patent expiration dates:
- June 28, 2031✓
- June 28, 2031
-
Synthetic progestogens and pharmaceutical compositions comprising the same
Patent 11,291,632
Issued: April 5, 2022
Inventor(s): Perrin Philippe & Velada Jose Luis & Drouin Dominique
Assignee(s): LABORATORIOS LEON FARMA SADescribed herein are synthetic progestogens, such as 6β,7β:15β,16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone, as well as pharmaceutical compositions comprising the same. Also described are methods of use.
Patent expiration dates:
- June 28, 2031✓
- June 28, 2031
-
Synthetic progestogens and pharmaceutical compositions comprising the same
Patent 11,291,633
Issued: April 5, 2022
Inventor(s): Perrin Philippe & Velada Jose Luis & Drouin Dominique
Assignee(s): LABORATORIOS LEON FARMA SADescribed herein are synthetic progestogens, such as 6β,7β:15β,16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone, as well as pharmaceutical compositions comprising the same. Also described are methods of use.
Patent expiration dates:
- June 28, 2031✓
- June 28, 2031
-
Synthetic progestogens and pharmaceutical compositions comprising the same
Patent 11,351,122
Issued: June 7, 2022
Inventor(s): Perrin; Philippe et al.
Assignee(s): LABORATORIOS LEON FARMA SA (Leon, ES)Described herein are synthetic progestogens, such as 6β,7β:15β,16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone, as well as pharmaceutical compositions comprising the same. Also described are methods of use.
Patent expiration dates:
- June 28, 2031✓
- June 28, 2031
-
Synthetic progestogens and pharmaceutical compositions comprising the same
Patent 11,413,249
Issued: August 16, 2022
Inventor(s): Perrin; Philippe et al.
Assignee(s): LABORATORIOS LEON FARMA SA (Leon, ES)Described herein are synthetic progestogens, such as 6β,7β:15β,16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone, as well as pharmaceutical compositions comprising the same. Also described are methods of use.
Patent expiration dates:
- June 28, 2031✓
- June 28, 2031
-
Synthetic progestogens and pharmaceutical compositions comprising the same
Patent 11,439,598
Issued: September 13, 2022
Inventor(s): Perrin Philippe & Velada Jose Luis & Drouin Dominique
Assignee(s): LABORATORIOS LEON FARMA SADescribed herein are synthetic progestogens, such as 6β,7β:15β,16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone, as well as pharmaceutical compositions comprising the same. Also described are methods of use.
Patent expiration dates:
- June 28, 2031✓
- June 28, 2031
-
Synthetic progestogens and pharmaceutical compositions comprising the same
Patent 11,478,487
Issued: October 25, 2022
Inventor(s): Perrin; Philippe et al.
Assignee(s): LABORATORIOS LEON FARMA SA (Leon, ES)Described herein are synthetic progestogens, such as 6β,7β:15β,16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone, as well as pharmaceutical compositions comprising the same. Also described are methods of use.
Patent expiration dates:
- June 28, 2031✓
- June 28, 2031
-
Synthetic progestogens and pharmaceutical compositions comprising the same
Patent 11,504,334
Issued: November 22, 2022
Inventor(s): Perrin; Philippe et al.
Assignee(s): LABORATORIOS LEON FARMA SA (Leon, ES)Described herein are synthetic progestogens, such as 6β,7β:15β,16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone, as well as pharmaceutical compositions comprising the same. Also described are methods of use.
Patent expiration dates:
- June 28, 2031✓
- June 28, 2031
-
Synthetic progestogens and pharmaceutical compositions comprising the same
Patent 11,951,213
Issued: April 9, 2024
Inventor(s): Perrin; Philippe et al.
Assignee(s): LABORATORIOS LEON FARMA SA (Leon, ES)Described herein are synthetic progestogens, such as 6β,7β:15β,16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone, as well as pharmaceutical compositions comprising the same. Also described are methods of use.
Patent expiration dates:
- June 28, 2031✓
- June 28, 2031
-
Synthetic progestogens and pharmaceutical compositions comprising the same
Patent 12,090,231
Issued: September 17, 2024
Inventor(s): Perrin; Philippe et al.
Assignee(s): LABORATORIOS LEON FARMA SA (Leon, ES)Described herein are synthetic progestogens, such as 6β,7β:15β,16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone, as well as pharmaceutical compositions comprising the same. Also described are methods of use.
Patent expiration dates:
- June 28, 2031✓
- June 28, 2031
-
Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Patent 9,603,860
Issued: March 28, 2017
Inventor(s): Perrin Philippe & Drouin Dominique & Boyer-Joubert Cécile
Assignee(s): LABORATORIOS LEON FARMA SAA pharmaceutical composition comprising an active contraceptive drug and one or more pharmaceutically-acceptable excipients. The pharmaceutical composition, when subjected to an in vitro dissolution test according to the USP XXIII Paddle Method, results in no more than 50% of said active drug initially present being dissolved within 30 minutes, and at least 50% of the active drug being dissolved in a time range from about 3 hours to about 4 hours. The pharmaceutical composition is administered daily to a patient having a BMI of about 25 kg/mor more for at least a portion of a treatment cycle. The pharmaceutical composition does not cause a number of days of bleeding events in the patient exceeding an average of 15% per treatment cycle in consecutive treatment cycles of administration after an initial treatment cycle of administration.
Patent expiration dates:
- June 28, 2031✓
- June 28, 2031
More about Slynd (drospirenone)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (386)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: progestins
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
